maria jose vargas

Lo q no se diagnostica no se trata 👏👏👏👏👏

Optimal glucocorticoid therapy in lupus nephritis doi.org/10.1093/ndt/gf…

Management of monoclonal gammopathy of renal significance: treatment standard academic.oup.com/ndt/article/41…

Single-center perspective of glomerular pathology in checkpoint inhibitor-treated patients @Arjun_Mohan1 @MPAlexanderMD @HerrmannMd @KIReports kireports.org/article/S2468-…

Basic evaluation of the kidney biopsy when you see an MPGN on light microscopy.

Membranoproliferative Glomerulonephritis (MPGN). I classified the disease into Immune complex (IC) MPGN and complement MPGN (now called C3G) back in 2011. The IC in IC-MPGN come from autoimmune dis, infections or monoclonal gammopathy. Careful and diligent work up will reveal the underlying etiology in >95% of IC-MPGN. Idiopathic or primary IC-MPGN is very rare in my opinion. Be careful of entrapment of Ig, these are C3G to begin with. And some cases of C3G may represent IC-MPGN, particularly in infections or in some cases where IC is minimal or may need unmasking. In this review, I describe the pitfalls in the diagnosis, practical considerations on biopsy findings of MPGN. kidney-international.org/article/S0085-…

Hidden In The Kidney: Renal-Limited Thrombotic Microangiopathy Without Hemolysis kireports.org/article/S2468-…

⁉️💊Is #Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to #Rituximab? 🌞 Grateful for the opportunity to pen this commentary on @KIReports under the guidance of the legendary @GlassockJ and Dr Fernando 👀kireports.org/article/S2468-… @ISNeducation @ISNkidneycare

New advances in the diagnosis and pathologic spectrum of monoclonal gammopathy of renal significance journals.lww.com/co-nephrolhype…

@kamleshkhunti @EASDnews @ADA_DiabetesPro @AskDrShashank @docwas @escardio @ACCinTouch @DiabetesUK @rcgp @IntDiabetesFed SGLT2i can only work, if your kidneys are hyperfiltrating and they usually don`t at low BMI (unless in DM) read this: academic.oup.com/ndt/advance-ar… and this: academic.oup.com/ndt/article/40…

What's New in Membranous Nephropathy and How to Incorporate New Antigen Discoveries into Clinical Practice? REVIEW by @LadanZand @fervenzafernan1 @SethiRenalPath bit.ly/3J9d1qO

🫀 SGLT2 inhibitors in underweight HF patients In a prospective study (BMI ~17, median age 81): • ❌ No reduction in CV death/HF hospitalisation • ⚠️ Higher all-cause hospitalisations • 📉 Further BMI reduction 📊 Benefits seen in HF trials may not translate to very low-BMI populations. #HeartFailure #SGLT2 #CardioMetabolic mdpi.com/2077-0383/15/5…

In this article I argue against using clinical remission as an endpoint for stopping IS therapy in lupus nephritis! There is a pro position, as well as moderator commentary. Hope you enjoy it! @asnpublications journals.lww.com/kidney360/cita…

“Science is not a collection of truths, but rather an exploration of mysteries not yet solved” ( Freeman Dyson). A statement worth remembering !!!

TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model ⁦@JCI_insight⁩ @VictorCuenca3 @MayoClinicNeph @onconephsociety #onconephrology First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/41785046/

In this article we show how the cancer incidence is higher in patients with PLA2R associated MN compared to general population- prostate cancer was one of the most common. Age appropriate cancer screening is essential in this group! mayoclinicproceedings.org/article/S0025-…

Cancer Incidence in PLA2R-Associated Membranous Nephropathy is increased compared to general population! Take a look of our new study, led by @LadanZand! @mvargas07 @jingmiao2019 @AnilaCara @GianMarcoB65728 mayoclinicproceedings.org/article/S0025-…

Would you prescribe Bactrim for a patient with glomerular disease receiving rituximab? We recently explored this question. I would love for you to take a look: sciencedirect.com/science/articl… It was a true team effort, led by @LadanZand @MayoClinicNeph we are excited to share the work

Published today✨ Real-world safety data for targeted-release budesonide (Nefecon) remain limited. We report a case of IgAN w/ significant systemic adverse effects associated w/ Nefecon — highlighting the need for close monitoring. @LadanZand @GlassockJ doi.org/10.1093/ckj/sf…

In this article we evaluated the efficacy of Bactrim in preventing infections in GN patients receiving RTX - its use is important in those with AAV and kidney involvement @jingmiao2019 This was an incredible amount of work and an amazing team effort! sciencedirect.com/science/articl…